Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

The AI race between OpenAI and Google is heating up with the release of GPT-5.2. How does it compare to Gemini 3? Credit: Avishek Das/SOPA Images/LightRocket via Getty Images OpenAI's latest AI model ...

Jake Paul and Anthony Joshua are mere hours away from their much-anticipated boxing fight in Miami. Win or lose, both will walk away much richer. The Daily Mail reported in November that the purse for ...

Jaguars quarterback Trevor Lawrence set a team record with six total touchdowns against the New York Jets. Lawrence became the first NFL player in history with five passing touchdowns, one rushing ...

Simplist is an online marketplace of mortgage lenders; human guidance is optional. You’ll make payments to a loan servicer, not to Simplist. Loans are not available in every state. Loan origination ...

Apple's latest phone has a lot in common with the previous model, but there are notable improvements to the camera, display and battery. Is it worth the upgrade? Abrar's interests include phones, ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. The market approach is a method for determining the value of an ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The Federal Reserve wrapped up 2025 with three rate cuts that brought the federal funds rate down to a range between 3.5% and 3.75%. That shift is rippling through the banking system, but not at the ...